
Figure 1


Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 394 11.0(10.1,12.4)
Motesanib 359 13.0(11.2,14.0)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168 176 184
Weeks
Placebo (N) 549 508 451 398 347 294 250 198 161 128 110 97 84 75 68 56 43 27 17 10 2 0 0 0
Motesanib (N) 541 487 435 391 347 296 266 222 172 132 112 100 88 81 75 59 43 29 17 7 3 1 1 0

METHOD OF TREATING NON-SMALL LUNG CANCER IN A POPULATION SUBSET
HEI, et al
Attorney Docket No. A-1629-WO-PCT

Figure 2




Figure 3





Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 76 15.5(10.8,19.3)
Motesanib 56 20.9(15.4,30.0)
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Weeks
Placebo (N) 112 108 91 75 65 55 42 31 28 26 22 9 3 0
Motesanib (N) 107 101 100 89 79 60 43 36 33 30 27 14 5 0

Figure 4


Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 96 4.5(3.9,5.7)
Motesanib 80 7.0(5.8,7.9)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136
Weeks
Placebo (N) 112 83 63 41 20 13 9 4 1 1 1 1 1 0 0 0 0 0
Motesanib (N) 107 98 81 60 33 22 14 9 6 5 4 3 2 2 2 2 1 0

METHOD OF TREATING NON-SMALL LUNG CANCER IN A POPULATION SUBSET
HEI, et al
Attorney Docket No. A-1629-WO-PCT

Figure 5



METHOD OF TREATING NON-SMALL LUNG CANCER IN A POPULATION SUBSET
HEI, et al
Attorney Docket No. A-1629-WO-PCT

Figure 6





Figure 7


Figure 14a-2.1 Progression Free Survival
Non-Squamous Full Analysis Set (Asia Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 101 5.3(4.0,5.7)
Motesanib 84 7.0(5.8,7.9)
0 8 16 24 32 40 48 56 64 72 80 88 96 104 112 120 128 136 144 152 160 168
Weeks
Placebo (N) 117 88 68 44 22 15 9 4 1 1 1 1 1 0 0 0 0 0 0 0 0 0
Motesanib (N) 110 101 83 62 34 23 15 10 7 6 4 3 2 2 2 2 2 2 2 2 2 0

METHOD OF TREATING NON-SMALL CELL LUNG CANCER IN A POPULATION SUBSET
HEI, ET AL
Attorney Docket No. A-1629-WO-PCT

Figure 8





Figure 9


Figure 14j-1.1 Overall Survival
Non-Squamous Full Analysis Set (Japan Only)
Kaplan-Meier Percent
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Trt
# of Subjects with Events
Median (95% CI) in Months
Placebo 35 20.7(13.5,27.4)
Motesanib 32 26.7(16.3,37.1)
0 16 32 48 64 80 96 112 128 144 160 176 192
Weeks
Placebo (N) 51 49 46 38 32 29 22 17 10 10 9 0 0
Motesanib (N) 56 55 49 42 39 34 29 20 16 13 12 5 0

METHOD OF TREATING NON-SMALL CELL LUNG CANCER IN A POPULATION SUBSET
HEI, ET AL
Attorney Docket No. A-1629-WO-PCT

Figure 10

